000 | 01940 a2200577 4500 | ||
---|---|---|---|
005 | 20250513054305.0 | ||
264 | 0 | _c19940715 | |
008 | 199407s 0 0 eng d | ||
022 | _a1073-449X | ||
024 | 7 |
_a10.1164/ajrccm.149.6.8004317 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWells, A U | |
245 | 0 | 0 |
_aFibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. _h[electronic resource] |
260 |
_bAmerican journal of respiratory and critical care medicine _cJun 1994 |
||
300 |
_a1583-90 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aBias |
650 | 0 | 4 | _aBiopsy |
650 | 0 | 4 | _aBlood Gas Analysis |
650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 |
_aDyspnea _xetiology |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aLung Volume Measurements |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aOdds Ratio |
650 | 0 | 4 |
_aPrednisolone _xtherapeutic use |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 |
_aPulmonary Fibrosis _xclassification |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 |
_aScleroderma, Systemic _xblood |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 |
_aSmoking _xadverse effects |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTomography, X-Ray Computed |
700 | 1 | _aCullinan, P | |
700 | 1 | _aHansell, D M | |
700 | 1 | _aRubens, M B | |
700 | 1 | _aBlack, C M | |
700 | 1 | _aNewman-Taylor, A J | |
700 | 1 | _aDu Bois, R M | |
773 | 0 |
_tAmerican journal of respiratory and critical care medicine _gvol. 149 _gno. 6 _gp. 1583-90 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1164/ajrccm.149.6.8004317 _zAvailable from publisher's website |
999 |
_c8003645 _d8003645 |